NEWS & EVENTS

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership.

Catalent announced a strategic collaboration with Galapagos NV to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications.

Catalent and Novo Holdings today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion.

Catalent and Novo Holdings today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days.

Catalent and Novo Holdings today announced that the European Commission has granted unconditional approval for the pending transaction under which Novo Holdings will acquire Catalent.

The MSA encompasses development of ISM-001 from cell line development through to finished clinical trial product supply; work will be performed in the USA and the EU.

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers:

Catalent announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden.

Catalent today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany.